Jpmorgan Chase & CO Humanigen, Inc Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.76 - $3.33 $40,645 - $76,903	-23,094 Reduced 99.7%	69 $0
Q1 2022 May 11, 2022	BUY	$1.81 - $3.97 $11,077 - $24,296	6,120 Added 35.91%	23,163 $70,000
Q4 2021 Feb 10, 2022	BUY	$3.66 - $8.22 $347 - $780	95 Added 0.56%	17,043 $63,000
Q3 2021 Nov 12, 2021	BUY	$5.93 - $17.83 $100,501 - $302,182	16,948 New	16,948 $100,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.